金萬林首席科學家介紹
首頁 > 關於我們 > 金萬林首席科學家介紹

  石瑜 教授  Yu Shyr, Ph.D.
Chairman, Department of Biostatistics
Director, Vanderbilt Center for Quantitative Sciences
Director, Vanderbilt Technologies for Advanced Genomics Analysis and Research Design
Harold L. Moses Chair in Cancer Research
Professor of Biostatistics, Biomedical Informatics, and Health Policy
Vanderbilt University Medical Center

石瑜教授於1994年在University of Michigan (Ann Arbor)獲得生物統計博士學位,隨後加入Vanderbilt大學醫學院。在Vanderbilt,他參與了許多研究項目:協助研究人員制定臨床研究方案,通過外部同行評審機制參加多項計畫,並開發了用於臨床試驗設計,高維數據前處理和估計parallel line bioassay中相對效力的生物統計學和生物資訊方法。

石教授是美國統計協會的會員,美國科學促進會的研究員和美國FDA顧問委員會投票成員。此外,他還在專業會議上發表了260多篇論文,並在各種期刊(h-index = 84)上發表了430多篇同行評審論文,如Nature、NEJM、JAMA、Cell、Lancet、Nature Medicine、JAMA Oncology、JCI、BMC BioinformaticsClinical Trials。 石教授還擔任美國癌症研究協會2018年計劃委員會的聯合主席,並且是美國國家醫學院(IOM)分子靶向治療生物標記物臨床開發政策問題委員會的成員。他曾擔任美國國家癌症研究所(NCI)發育治療研究科,癌症免疫病理學和免疫治療研究科以及人口和患者導向培訓研究科的成員。他還曾在眾多NIH / NCI SPORE,P01和CCSG審查小組/委員會以及美國陸軍醫學研究乳腺癌研究計劃(BCRP)的流行病學部門任職。石教授曾在ASCO教育部門擔任臨床試驗設計和方法學高級概念的特邀講者,並且是AACR / ASCO臨床癌症研究Vail研討會的共同課程主任。除此之外,他在世界各處籌備了統計研討會,並在比利時,加拿大,荷蘭,德國,奧地利,中國,日本,新加坡,台灣,沙特阿拉伯和馬來西亞等國家演講。他目前也是Northwestern UniversityDartmouth College Moffitt Cancer Center等15個外部機構的顧問委員會成員。

石教授是Clinical Cancer ResearchCancer and Cancer Prevention Research Journal以及ASCO癌症研究委員會的編輯委員會成員,並擔任JAMA OncologyJournal of Thoracic Oncology的副主編,PLoS ONE統計顧問委員會成員,以及Science reviewer。他還為NCI資助的Vanderbilt University Breast Cancer SPOREGI Cancer SPORE和其他項目管理生物統計和生物資訊核心實驗室。此外,石教授是NCI U01 grant of Barrett’s esophagus translational research network coordinating center的計畫主持人,以及NCI U24 grant of Small cell lung cancer consortium coordinating center的Vanderbilt計畫主持人。 石教授目前的研究興趣集中在開發用於分析新一代定序數據的統計與生物資訊方法,包括一系列關於評估進行DNA和RNA定序研究的sample size的論文。

 

Yu Shyr received his Ph.D. in biostatistics from the University of Michigan (Ann Arbor) in 1994 and subsequently joined the faculty at Vanderbilt University School of Medicine. At Vanderbilt, he has collaborated on numerous research projects; assisted investigators in developing clinical research protocols; collaborated on multiple grants funded through external peer-reviewed mechanisms; and developed biostatistical and bioinformatic methodologies for clinical trial design, high-dimensional data preprocessing, and estimating relative potency in a parallel line bioassay.

Dr. Shyr is a Fellow of the American Statistical Association (ASA), an elected fellow of the American Association for the Advancement of Science (AAAS) and a US Food and Drug Administration (FDA) advisory committee voting member. He has delivered more than 250 abstracts at professional meetings and published more than 430 peer-reviewed papers in a variety of journals (h-index = 88), such as Nature, NEJM, JAMA, Cell, Lancet, Nature Medicine, Nature Protocols, JAMA Oncology, JCI, Bioinformatics, BMC Bioinformatics, Clinical Trials, Statistics in Medicine, and Computational Statistics and Data Analysis. He was the member of the US National Academy of Medicine (IOM) Committee on Policy Issues in the Clinical Development of Biomarkers for Molecularly Targeted Therapies. He has served as a member of the US National Cancer Institute (NCI) Developmental Therapeutics Study Section, Cancer Immunopathology and Immunotherapy Study Section and the Population and Patient-oriented Training Study Section; he also has served on numerous NIH/NCI SPORE, P01, and CCSG review panels/committees, as well as the epidemiology section of the U.S. Army Medical Research and Materiel Command Breast Cancer Research Program (BCRP). Dr. Shyr has presented as an invited faculty member in the ASCO Educational Section on Advanced Concepts in Clinical Trial Design and Methodology and he was the co-course director for the AACR/ASCO Methods in Clinical Cancer Research Vail Workshop. In addition to this, he has prepared statistical workshops worldwide and presented them in countries, such as, Belgium, Canada, France, the Netherlands, Germany, Austria, China, Japan, Singapore, Saudi Arabia, Malaysia, Taiwan, and Hong Kong. He currently serves on 15 external advisory boards for institutions including Yale University, Northwestern University, Dartmouth College, UT Southwestern, OHSU, University of Colorado, and Moffitt Cancer Center; is a member of the editorial board for the Journal of Clinical Oncology, JNCI, Clinical Cancer Research, Cancer and Cancer Prevention Research Journal as well as ASCO’s Cancer Research Committee; and directs the biostatistics and bioinformatics cores for the NCI-funded Vanderbilt University Breast Cancer SPORE, GI Cancer SPORE, and other program projects. He is the Associate Editor for JAMA Oncology, Journal of Thoracic Oncology (JTO), and the Statistical Advisory Board Member for PLoS ONE. In addition, Dr. Shyr is the principle investigator of the NCI U01 grant of Barrett’s esophagus translational research network coordinating center (BETRNetCC). Dr. Shyr’s current research interests focus on developing statistical bioinformatic methods for analyzing next-generation sequencing data based on single cell technology including a series of papers on estimating the sample size requirements for studies conducting DNA and RNA sequencing analysis.